Graham R. Foster, FRCP, PhD, provides expert opinion on how to avoid the development of HCV resistance with new direct-acting antiviral regimens.
Graham R. Foster, FRCP, PhD, provides expert opinion on how to avoid the development of HCV resistance with new direct-acting antiviral regimens through review of 4 patient cases.
Join Stephane Chevaliez, PharmD, PhD; Paul J. Pockros, MD; and Stefan Zeuzem, MD, as they review and discuss key principles of HCV resistance with currently approved direct-acting antiviral agents, the latest resistance data on agents in development, and important considerations for potential future anti-HCV regimens. These expert faculty members also provide practical strategies for clinical challenges with the newly approved direct-acting agents through a case-based analysis.
Christoph Sarrazin, MD, reviews highlights on resistance to direct-acting antiviral agents from the 2011 American Association for the Study of Liver Diseases conference.
Jean-Michel Pawlotsky, MD, PhD, emphasizes the importance of optimal drug exposure and adherence levels to avoid the development of resistant hepatitis C virus variants, along with strategies to optimize adherence rates.
In this Expert Viewpoint, Geoffrey M. Dusheiko, MD, FCP(SA), FRCP, reviews the clinical implications of emerging data on drug resistance in patients treated with currently approved HCV protease inhibitors.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.